vimarsana.com
Home
Live Updates
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity : vimarsana.com
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Michael Miller ,
Ttirzepatide Mounjaro ,
Semaglutide Wegovy ,
Marshallh Woodworth ,
Nasdaq ,
Donga St Co ,
Neurobo Pharmaceuticals Inc ,
Drug Administration ,
Neurobo Pharmaceuticals ,
Prnewswire Neurobo Pharmaceuticals Inc ,
Preclinical Studies Show ,
Superior Weight Loss Compared ,
Similar Weight Loss Compared ,
While Consuming More ,
Trial Expected ,
First Half ,
Investigational New Drug ,
Hyung Heon Kim ,
Chief Executive Officer ,
Metabolic Dysfunction Associated Steatohepatitis ,
Private Securities Litigation Reform Act ,
Nc ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Clinical Trials Amp Medical Discoveries ,
Fda Approval ,
vimarsana.com © 2020. All Rights Reserved.